The president of AstraZeneca France, Olivier Nataf, said on 27 November 2020 that the situation regarding the COVID-19 vaccine being developed by AstraZeneca is generally encouraging, even though a new trial will be needed, Reuters news agency reported on Friday.
Nataf was quoted as telling RTL radio: "We are in a context that is encouraging."
However, British pharmaceutical company AstraZeneca faces questions about its success rate, which some experts say could hinder its chances of gaining speedy US and EU regulatory approval, Reuters added.
Dr. Reddy's Receives Approval to Conduct Phase 3 Clinical Trial for Sputnik V Vaccine in India
Carbon Health Launches COVID-19 Vaccination Platform to Accelerate National Rollout
Kyruus Enables Online Scheduling for COVID-19 Vaccine Visits
China's Sinopharm says COVID-19 vaccine safe for children and teenagers
Publix and the State of Florida to Bring COVID-19 Vaccinations to Three Florida Counties
OnSolve's CodeRed used across the US for the management of information related to COVID-19 vaccine
Meijer Pharmacies to administer COVID-19 vaccines in the State of Michigan
China's CanSino Biologics COVID-19 vaccine shows high antibody levels in Russian trials
Hungary's government signs deal with China's Sinopharm for COVID-19 vaccine purchase
Meijer collaborates with the State of Michigan for COVID-19 vaccine administration
African Union secures 270 million COVID-19 vaccine doses from WHO's COVAX initiative